Search results for "alkyne"

showing 10 items of 141 documents

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

2015

ABSTRACT Between 22 and 45% of HIV-positive subjects are likely to report symptoms of depression. Considering this background, a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor efavirenz (EFV) and two antidepressants, sertraline (SRT) and nortriptyline (NT), was studied. Rats were administered EFV alone or together with the antidepressants, and changes in the plasma levels and pharmacokinetic parameters of EFV were analyzed. Additional in vitro experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effect of SRT and NT on EFV metabolism by determining the formation rate of the major EFV metabolite (8-OH-E…

CyclopropanesMalemedicine.medical_specialtyEfavirenzAnti-HIV AgentsMetaboliteNortriptylinePharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsIn vivoInternal medicineSertralinemedicineAnimalsHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRats WistarIC50PharmacologyChemistryAntidepressive AgentsBenzoxazinesInfectious DiseasesEndocrinologyAlkynesMicrosomeMicrosomes LiverReverse Transcriptase InhibitorsNortriptylinehuman activitiesDrug metabolismmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells

2014

Abstract The anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in cultured neurons and glial cells. Nitric oxide (NO) is a mediator of mitochondrial dysfunction associated with HIV central nervous system symptoms. We show that EFV promotes inducible nitric oxide synthase (iNOS) expression in cultured glial cells and generated NO undermines their mitochondrial function, as inhibition of NOS partially reverses this effect. EFV inhibits mitochondrial Complex I in both neurons and glia; however, when the latter cells are treated for longer periods, other mitochondrial complexes are also affected in accordance with the increased NO production. These findi…

CyclopropanesNNRTIEfavirenzAnti-HIV AgentsCentral nervous systemNitric Oxide Synthase Type IIMitochondrionBiologyNitric OxideNitric oxideCell Linechemistry.chemical_compoundMediatornitric oxidemedicineImmunology and AllergyHumansNeuronsNeurotoxicityelectron transport chainHIVefavirenzmedicine.diseasecentral nervous systemCell biologyBenzoxazinesMitochondriaNitric oxide synthasemitochondriaInfectious Diseasesmedicine.anatomical_structurechemistryAlkynesImmunologybiology.proteinNeurogliaNeuroglia
researchProduct

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir i…

2013

Objectives: To explore the durability of three first-line tenofovir/emtricitabine-based regimens in combination with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in HIV-1-infected patients. Patients and methods: A retrospective, longitudinal, multicentre analysis of adult patients enrolled in the Antiretroviral Resistance Cohort Analysis (ARCA), a national prospective observational cohort of HIV-1-infected patients followed up at more than 100 clinical and laboratory units in Italy. Patients eligible were those starting first-line antiretroviral therapy between 1 June 2004 and 15 April 2011 and who were followed up for at least 6 months. The primary endpoint was durability, define…

CyclopropanesTime FactorsPyridinesPyridineDrug ResistanceLopinavir/ritonavirLongitudinal StudieHIV InfectionsPharmacologyAntiviral therapyDeoxycytidineLopinavirCohort Studieschemistry.chemical_compoundimmune system diseasesRetrospective StudieOrganophosphonateMedicineEmtricitabineHIV InfectionPharmacology (medical)ViralLongitudinal StudiesProspective StudiesProspective cohort studyvirus diseasesLopinavirInfectious DiseasesAnti-Retroviral AgentsItalyAlkynesCombinationOligopeptideHIV/AIDSDrug Therapy CombinationOligopeptidesmedicine.drugHumanMicrobiology (medical)Benzoxazinemedicine.medical_specialtyEfavirenzTime Factorantiretroviral therapyAtazanavir SulfateOrganophosphonatesfirst-line therapy tenofovir emtricitabine atazanavir/ritonavirSettore MED/17 - MALATTIE INFETTIVEEmtricitabineDurabilityDrug TherapyInternal medicineDrug Resistance ViralDrug utilizationHumansAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Time Factors; Pharmacology; Pharmacology (medical); Infectious DiseasesTenofovirRetrospective StudiesAntiviral therapy; Drug utilization; Durability; HIV/AIDS; Tenofovir/emtricitabine; Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Deoxycytidine; Drug Resistance Viral; Drug Therapy Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time FactorsPharmacologyRitonavirbusiness.industryAdenineAtazanavirBenzoxazinesRegimenProspective StudiechemistryHIV-1RitonavirAnti-Retroviral AgentCohort StudieTenofovir/emtricitabinebusiness
researchProduct

Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.

2021

Integrase inhibitors appear to increase body weight, but paradoxically some data indicate that raltegravir (RAL) may decrease liver fat. Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD). We randomized overweight PLWH with signs of metabolic syndrome to switch a PI or EFV to RAL (

Cyclopropanesmedicine.medical_specialtyanimal structuresEfavirenzIntegrase inhibitorAdipose tissueHIV Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdipocyteInternal medicineRaltegravir PotassiumNonalcoholic fatty liver diseasemedicineHumansProtease inhibitor (pharmacology)Protease Inhibitors030212 general & internal medicinebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseRaltegravir3. Good healthBenzoxazinesInfectious DiseasesEndocrinologychemistryAdipose TissueLiverAlkynesBody Composition030211 gastroenterology & hepatologymedicine.symptombusinessWeight gainmedicine.drugAIDS patient care and STDs
researchProduct

Reactions of Alkenes and Alkynes with an Acyclic Silylene and Heavier Tetrylenes under Ambient Conditions

2014

Cycloaddition reactions of the acyclic silylene Si(SAriPr4)2 (AriPr4 = C6H3-2,6(C6H3-2,6-iPr2)2) with a variety of alkenes and alkynes were investigated. Its reactions with the alkynes phenylacetylene and diphenylacetylene and the diene 2,3-dimethyl-1,3-butadiene yielded silacycles (AriPr4S)2tiebar above startSi(CH═tiebar above endCPh) (1), (AriPr4S)2tiebar above startSi(PhC═tiebar above endCPh) (2), and (AriPr4S)2tiebar above startSiCH2CMeCMetiebar above endCH2 (3) at ambient temperature. The compounds were characterized by X-ray crystallography, 1H, 13C, and 29Si NMR spectroscopy, and IR spectroscopy. No reaction was observed with more substituted alkenes such as propene, (Z)-2-butene, te…

DieneTrimethylsilylacyclic silyleneAlkynealkeenit ja alkyynitPhotochemistryMedicinal chemistryInorganic Chemistrychemistry.chemical_compoundraskaammat tetryleenitalkenes and alkynesCyclopenteneambient conditionssykloadditioreaktiotPhysical and Theoretical Chemistryasyklinen silyleeniDiphenylacetyleneta116chemistry.chemical_classificationOrganic ChemistrySilylenecyloaddition reactionsCycloadditionPhenylacetylenechemistrynormaalit ympäristön olosuhteethevier tetrylenes
researchProduct

A Homoleptic Alkynyl‐Ligated [Au 13 Ag 16 L 24 ] 3− Cluster as a Catalytically Active Eight‐Electron Superatom

2020

A new alkynylated cluster [Au13 Ag16 (C10 H6 NO)24 ]3- is prepared by a NaBH4 mediated reduction method. The AuAg clusters are confirmed by sophisticated characterization techniques. It has a unique "Aucenter @Ag12 @Au12 Ag4 " metal framework which is protected by 24 atypical alkyne ligands L (L=C10 H6 NO). The ligands construct a unique type of motif L-(Ag)-Au-(Ag)-L at the cluster interface, where the alkyne (C≡C) group of each L was linked by sharing an Au atom through the σ bonds and each C≡C group was discretely connected to a chemically different Ag atom (Agicosahedral /Agcap ) through π bonds. The electronic and optical properties of [Au13 Ag16 L24 ]3- were studied. DFT characterized…

Diethylaminechemistry.chemical_classificationAbsorption spectroscopy010405 organic chemistrySuperatomAlkyneGeneral Chemistry010402 general chemistry01 natural sciencesCatalysisCoupling reaction0104 chemical scienceschemistry.chemical_compoundCrystallographychemistryPhenylacetyleneCluster (physics)HomolepticAngewandte Chemie International Edition
researchProduct

Biowaiver monographs for immediate release solid oral dosage forms: efavirenz.

2013

Literature data pertaining to the decision to allow a waiver of in vivo bioequiv- alence testing for the approval of immediate-release (IR) solid oral dosage forms containing efavirenz as the only active pharmaceutical ingredient (API) are reviewed. Because of lack of conclusive data about efavirenz's permeability and its failure to comply with the "high solu- bility" criteria according to the Biopharmaceutics Classification System (BCS), the API can be classified as BCS Class II/IV. In line with the solubility characteristics, the innovator product does not meet the dissolution criteria for a "rapidly dissolving product." Furthermore, product variations containing commonly used excipients …

DrugCyclopropanesEfavirenzTime FactorsAnti-HIV Agentsmedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyDosage formBiopharmaceuticschemistry.chemical_compoundInnovatorAnimalsHumansRegulatory scienceImmediate releasemedia_commonActive ingredientChemistryBiopharmaceutics Classification SystemBenzoxazinesSolubilityTherapeutic EquivalencyAlkynesJournal of pharmaceutical sciences
researchProduct

Unravelling the strain-promoted [3+2] cycloaddition reactions of phenyl azide with cycloalkynes from the molecular electron density theory perspective

2020

The strain-promoted [3+2] cycloaddition (SP-32CA) reactions of phenyl azide with a series of five strained cycloalkynes C5–C9 have been studied within molecular electron density theory (MEDT) at the MPWB1K/6-311G(d,p) computational level. These zwitterionic type SP-32CA reactions take place through a one-step mechanism, with activation enthalpies in acetonitrile between −4.2 and 19.9 kcal mol−1. An excellent linear correlation between the decrease in activation enthalpies and the ring size of this series of cycloalkynes can be established. The present study shows that the highly strained cycloalkynes C5 and C6 experience a different chemical reactivity than less strained cycloalkynes C7–C9,…

Electron densityChemistryKineticsCycloalkyneGeneral ChemistryCatalysisCycloadditionRing sizechemistry.chemical_compoundComputational chemistryPhenyl azideElectrophileMaterials ChemistryAcetonitrileNew Journal of Chemistry
researchProduct

Partial Reduction and Selective Transfer of Hydrogen Chloride on Catalytic Gold Nanoparticles

2017

© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim HCl in solution accepts electron density from Au NPs and partially reduces at room temperature, as occurs with other simple diatomic molecules, such as O2 and H2. The activation can be run catalytically in the presence of alkynes to give exclusively E-vinyl chlorides, after the regio- and stereoselective transfer of HCl. Based also on this method, vinyl chloride monomer (VCM) can be produced in a milder and greener way than current industrial processes.

Electron densityInorganic chemistryhydrochlorinationPhotochemistry010402 general chemistryalkynes01 natural sciencesCatalysisVinyl chlorideCatalysischemistry.chemical_compoundvinyl chloridesHydrogen chloride010405 organic chemistryOrganic ChemistryGeneral ChemistryGeneral MedicinegoldDiatomic molecule0104 chemical sciencesMonomerheterogeneous catalysischemistryColloidal goldChemical SciencesStereoselectivity
researchProduct

Polymerization of Ethylene Oxide, Propylene Oxide, and Other Alkylene Oxides: Synthesis, Novel Polymer Architectures, and Bioconjugation.

2015

The review summarizes current trends and developments in the polymerization of alkylene oxides in the last two decades since 1995, with a particular focus on the most important epoxide monomers ethylene oxide (EO), propylene oxide (PO), and butylene oxide (BO). Classical synthetic pathways, i.e., anionic polymerization, coordination polymerization, and cationic polymerization of epoxides (oxiranes), are briefly reviewed. The main focus of the review lies on more recent and in some cases metal-free methods for epoxide polymerization, i.e., the activated monomer strategy, the use of organocatalysts, such as N-heterocyclic carbenes (NHCs) and N-heterocyclic olefins (NHOs) as well as phosphazen…

Ethylene OxidePolymersEpoxide02 engineering and technology010402 general chemistry01 natural sciencesPolymerizationchemistry.chemical_compoundPolymer chemistryCopolymerOrganic chemistryPropylene oxideEthylene oxideMolecular StructureCationic polymerizationOxidesGeneral Chemistry021001 nanoscience & nanotechnology0104 chemical sciencesAnionic addition polymerizationchemistryPolymerizationAlkynesCoordination polymerizationEpoxy Compounds0210 nano-technologyChemical reviews
researchProduct